Go Pro

Desjardins' Rating of Apotex Health on 9/18/2026

On September 18, 2026, Desjardins updated its outlook on Apotex Health (TSE:APT) with the action "Upgrade", setting a "Moderate Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Desjardins

DateCompanyAction
9/24/2026
Kinross Gold Co. stock logo
K
Kinross Gold
Lower Price Target
9/24/2026
AGF Management Limited stock logo
AGF.B
AGF Management
Lower Price Target
9/23/2026
Volatus Aerospace Inc. stock logo
FLT
Volatus Aerospace
Set Price Target
9/22/2026
Capstone Copper Corp. stock logo
CS
Capstone Copper
Set Price Target
9/17/2026
Dollarama Inc. stock logo
DOL
Dollarama
Lower Price Target
9/17/2026
BCE Inc. stock logo
BCE
BCE
Boost Price Target
More Ratings From Desjardins